The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer ...

Eliquis sales grew 11% compared with the same ... Bristol is working through a $1.5 billion cost-reduction program, ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.